Tim Meyer
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
Papers in
- Oncology 103
- Lung Cancer Research Studies 29
- Cancer Immunotherapy and Biomarkers 23
- Pancreatic and Hepatic Oncology Research 21
- Colorectal Cancer Treatments and Studies 18
- Hepatology 97
- Hepatocellular Carcinoma Treatment and Prognosis 95
- Co-authors
- Andrew K. Burroughs (14 shared papers)Anna Saborowski (2 shared papers)Gonzalo Sapisochín (2 shared papers)Riad Salem (1 shared paper)Arndt Vogel (1 shared paper)Josep M. Llovet (16 shared papers)Gordon Rustin (3 shared papers)Bruno Sangro (19 shared papers)
- Journals
- Journal of Clinical Oncology (54 papers)Annals of Oncology (29 papers)British Journal of Cancer (15 papers)Journal of Hepatology (13 papers)European Journal of Cancer (7 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Tim Meyer
233 papers receiving 14.4k citations
Tim Meyer's Hit Papers
Peers
Comparison fields: 5 of 130
- Hepatology 6.3k
- Oncology 3.6k
- Cancer Research 1.5k
- Epidemiology 3.0k
- Pathology and Forensic Medicine 1.2k
Countries citing papers authored by Tim Meyer
This map shows the geographic impact of Tim Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Meyer more than expected).
Fields of papers citing papers by Tim Meyer
This network shows the impact of papers produced by Tim Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Meyer. The network helps show where Tim Meyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Tim Meyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 240 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hepatocellular carcinoma Hit paper breakdown → | 2022 | 1458 |
| 2 | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Hit paper breakdown → | 2020 | 877 |
| 3 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2018 | 734 |
| 4 | Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Hit paper breakdown → | 2021 | 682 |
| 5 | Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies Hit paper breakdown → | 2006 | 641 |
| 6 | A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability Hit paper breakdown → | 2012 | 523 |
| 7 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial Hit paper breakdown → | 2017 | 346 |
| 8 | Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial Hit paper breakdown → | 2019 | 317 |
| 9 | Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines Hit paper breakdown → | 2021 | 314 |
| 10 | 2013 | 261 | |
| 11 | 2011 | 261 | |
| 12 | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference Hit paper breakdown → | 2020 | 253 |
| 13 | 2016 | 245 | |
| 14 | PKC412--a protein kinase inhibitor with a broad therapeutic potential. | 2000 | 245 |
| 15 | 2010 | 224 | |
| 16 | 2000 | 221 | |
| 17 | EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Hit paper breakdown → | 2024 | 213 |
| 18 | 2019 | 208 | |
| 19 | 2009 | 208 | |
| 20 | 2020 | 198 |
About Tim Meyer
Tim Meyer is a scholar working on Oncology, Hepatology, Epidemiology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 240 papers that have together received 14.6k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (95 papers), Neuroendocrine Tumor Research Advances (49 papers), Lung Cancer Research Studies (29 papers), Neuroblastoma Research and Treatments (24 papers), Cancer Immunotherapy and Biomarkers (23 papers), Pancreatic and Hepatic Oncology Research (21 papers), Colorectal Cancer Treatments and Studies (18 papers) and Liver Disease Diagnosis and Treatment (14 papers). The work is most often cited by research in Hepatology (6.3k citations), Oncology (3.6k citations), Cancer Research (1.5k citations), Epidemiology (3.0k citations) and Pathology and Forensic Medicine (1.2k citations). Tim Meyer has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Andrew K. Burroughs, Anna Saborowski, Gonzalo Sapisochín, Riad Salem, Arndt Vogel, Josep M. Llovet, Gordon Rustin, Bruno Sangro, Martyn Caplin and Tu Vinh Luong. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Journal of Hepatology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.